1 |
Predictors of intermediate-term survival with destination locoregional therapy of hepatocellular cancer in patients either ineligible or unwilling for liver transplantationRamanathan, Meera, Shroads, Michael, Choi, Myunghan, Wood, David, Seetharam, Anil 10 1900 (has links)
Intra-arterial or percutaneous locoregional therapies (LRT) are often employed to maintain potential liver transplant (LT) recipients with hepatocellular carcinoma (HCC) within T2/Milan criteria. Predictors of survival when LRT is used as destination therapy in those who are either ineligible or unwilling for LT remain poorly defined. We evaluated predictors of 3-year survival with destination LRT in a population of cirrhotic patients diagnosed with HCC, presenting within T2 criteria, and either ineligible or unwilling for LT. The cohort surviving 3 years had a significantly lower model for end-stage liver disease (MELD) score at HCC diagnosis (9.7 vs. 11.4, P= 0.037) and MELD following initial locoregional therapy (10.7 vs. 13.3, P= 0.008) compared to those not surviving three years despite similar demographic, tumor, and treatment variables. LRT as destination therapy results in modest intermediate term survival, with liver function at presentation and immediately following initiation of LRT predicting intermediate survival with this approach.
|
2 |
Effectiveness of Radiofrequency Ablation of Initial Recurrent Hepatocellular Carcinoma after Hepatectomy: Long-Term Results and Prognostic Factors / 肝切除術後の肝細胞癌初回再発に対するラジオ波焼灼術時の有用性の検討:長期予後と予後予測因子Shinozuka, Ken 23 January 2018 (has links)
京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第20809号 / 医博第4309号 / 新制||医||1025(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 妹尾 浩, 教授 坂井 義治, 教授 戸井 雅和 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM
|
3 |
Interaction between dietary iron overload and aflatoxin B1 in hepatocarcinogenesis using an experimental rat modelBronze, Michelle Saltao 22 February 2007 (has links)
Student Number : 9902006N -
MSc(Med) Dissertation -
School of Medicine -
Faculty of Health Sciences / Hepatocellular carcinoma (HCC) is the most common primary malignant tumour of
the liver. Aflatoxin B1 (AFB1) is a potent hepatocarcinogen, and dietary iron overload
has been shown to contribute to HCC development in black africans. Both are well
studied hepatotoxins. The aim of this study was to use a Wistar rat model over a 12
month period to investigate synergy and the extent thereof between AFB1 ingestion
and dietary iron overload. 25ug/day of AFB1, reconstituted in DMSO, was
administered by gavaging the animals, over a period of 10 days with a 2 day interval
in between. The chow diet was supplemented with 0.75% (w/w) ferrocene iron.
Experimental subjects were divided into 4 groups. Group 1 was fed the normal chow
diet. Group 2 was fed 0.75% (w/w) ferrocene iron alone. Group 3 was gavaged 250μg
AFB1 alone. Group 4 was fed the 0.75% (w/w) ferrocene iron and gavaged 250μg
AFB1. A number of assays were conducted to investigate synergy. Colorimetric assays
were used to measure serum iron, total-iron binding capacity, ALT, AST, GGT, nitrite
production, lipid peroxidation and hydroxyproline concentrations. ELISA’s were used
to determine ferritin, 8-isoprostane and 8-hydroxyguanosine concentrations. Nontransferrin
bound iron was measured using an HPLC method. A chemiluminescent
assay was used to measure superoxide anion production. Cytokines were measured
using a suspension array system. Mutagenicity was assessed using the Ames
mutagenicity assay using salmonella typhimirium strains TA97, TA98, TA100 and
TA102. Iron profiling indicated that iron overloading occurred with the ingestion of
the ferrocene diet. Biomarkers of oxidative stress, as illustrated by the measurement
of 8-hydroxyguanosine and lipid peroxidation, showed additive synergistic effects
between the two carcinogens. The anti-inflammatory interleukin-10 was shown to be
markedly elevated with the co-administration of the two carcinogens, indicating the elevated inflammatory processes. Additive synergistic effects were noted in terms of
the liver disease marker ALT. The salmonella typhimirium strain TA102 used in the
Ames mutagenicity test showed increased colony counts with respect to the coadministration
of carcinogens (P<0.05), although no synergistic effect was noted. In a
few of the presented parameters, the AFB1 group was not significantly different to the
control group, although significant differences between the Fe group and the Fe +
AFB1 groups were noted. The implication of which is that the presence of AFB1 is
increasing the activity of Fe as a carcinogen, thereby acting as a co-carcinogen.
Examples of such parameters illustrating this are presented in the results section
including serum ALT, serum nitrite, liver and serum lipid peroxidation, liver and
serum 8-hydroxyguanosine, some of the mutagenicity assays, and interleukin-10.
The conclusion of this study suggests that AFB1 acts as a co-carcinogen in the
presence of iron overloading, implying that a synergistic relationship between these
two toxins exists.
|
4 |
Développement de virus HSV-1 (virus de l’herpes simplex de type 1) oncolytiques ciblés pour traiter les carcinomes hépatocellulaires / Oncolytic HSV-1 (herpes simplex virus type 1) transcriptionally targeted against hepatocellular carcinomaPourchet, Aldo Decio 28 September 2010 (has links)
Le premier objectif a été de sélectionner des promoteurs de gènes cellulaires actifs spécifiquement dans les HCC à l’aide d’une recherche bibliographique puis en utilisant la base de donnée UniGene. Leur activité a été vérifiée par RT-qPCR et CHIP dans des lignées modèles HCC et dans des hépatocytes. Ces promoteurs ont été clonés en amont de la luciférase dans la région intergénique 20 du génome HSV-1 afin d’étudier leur force d’activité, 2 types de cinétiques et leur activité différentielle en fonction du type cellulaire et dans le contexte d’une infection virale. Le deuxième objectif a été de construire des virus oncolytiques ciblés pour l’expression de la protéine Us3, une protéine virale impliquée dans le contrôle de la réponse apoptotique induite par HSV-1. L’expression de la protéine Us3 est placée sous contrôle d’un promoteur cellulaire spécifique d’HCC. L’hypothèse est qu’en l’absence d’activité du promoteur cellulaire dans les cellules non HCC, la protéine Us3 ne sera pas synthétisée et, par conséquent, l’apoptose qui ne sera pas réprimée, inhibera le cycle de réplication et par conséquent, la production virale dans les cellules saines. Dans les cellules HCC, le promoteur actif permettra la réplication virale aboutissant à la destruction de lamasse tumorale. Un virus HSV-1 Us3- a été construit en utilisant la technique de recombinaison en plasmide BAC (Bacterial artificial chromosome), puis 2 virus oncolytiques en réintroduisant le gène Us3 sous contrôle du promoteur ANGPTL3 ou du promoteur HRE (hypoxia responsive element). Leur comportement oncolytique a été étudié en réalisant des courbes de croissance sur lignées cellulaires d’HCC et cellules hepatocyte-like. / Our long-term purpose is to develop transcriptionally targeted oncolytic vectors, derived from herpes simplex virus type 1 (HSV-1), designed to eradicate hepatocellular carcinomas (HCC). We have identified several HCC-specific promoters, as well as other cancer-specific promoters, that maintain their specificity when expressed from the virus genome. More precisely, we have demonstrated that these promoters are able to drive reporter gene (luciferase) expression from the virus genome in HCC-derived cells, both in cultured cells and in nude mice, but not in fresh human hepatocytes or in the WRL38 hepatocyte-like cells. HSV-1 infection induces, but then inhibits, a cellular antiviral apoptotic response, and the early virus protein US3 is a key actor in inhibiting apoptosis. We have hypothesized that inhibition of US3 expression in hepatocytes should led to early apoptotic death of these cells, therefore precluding virus multiplication and spread. In contrast, expression of US3 in cancer cells is expected to block apoptosis, leading to the achievement of the virus life cycle, cell lysis, and virus spread within the tumours. We report in this communication the construction and properties of two different potentially oncolytic HSV-1 vectors. One of them expresses US3 protein under the control of the HCC-specific promoter ANGPTL3, while the second promoter contains 9 repeats of the hypoxia responsive elements of vascular-endothelial growth factor (VEGF) (9xHRE promoter). Growth curves of these viruses were performed on different HCC cell lines to show their oncolytic properties.
|
5 |
Role of microRNAs in HepatocarcinogenesisWang, Bo 18 June 2012 (has links)
No description available.
|
6 |
Verstärkung des bystander Effektes von SuizidgentherapeutikaHillemann, Annett 27 March 2005 (has links)
Die vorliegende Arbeit beschäftigt sich mit einem neuartigen proteinbasierten, suizidgentherapeutischen Ansatz zur sicheren und effektiven Behandlung von soliden Tumoren. Verwendet wurden zellpermeable Fusionsproteine auf der Grundlage des bakteriellen Enzyms Cytosin Desaminase, welches spezifisch die Umsetzung der inaktive, nichttoxische Substanz (Prodroge) 5-Fluorcytosin in den hochwirksamen, stark toxischen Wirkstoff 5-Fluoruracil katalysiert. Dieser bewirkt die selektive Zerstörung von Tumorzellen. Durch die Fusion der bakteriellen Cytosin Desaminase (bCD) mit der Sequenz des Zellpermeabilität vermittelnden Peptides HBV-Translokationsmotiv (TLM) des Hepatits B-Virus (HBV) wurden zunächst zellpermeable E.coli Cytosin Desaminase Suizidfusionskonstrukte generiert. Für die bakteriell synthetisierten HBV-TLM-Fusionsproteine konnten eine Hexamerisierung sowie eine spezifische enzymatische Aktivität bei der Umsetzung von Cytosin zu Uracil als strukturelle und funktionelle Voraussetzungen für einen Einsatz in der Suizidgentherapie nachgewiesen werden, die vergleichbar mit dem wt-Protein waren. Bei Versuchen zur Internalisierung der zellpermeablen Fusionsproteine wurde für die Fusionsproteine mit C-terminal fusioniertem HBV-TLM (bCD-HBV-TLM) eine Aufnahme in das Zytoplasma von Hepatomzellen mittels konfokaler Laserscanmikroskopie und differentieller Zellfraktionierung nachgewiesen, nicht jedoch für Fusionsproteine mit N-terminalem HBV-TLM (HBV-TLM-bCD). Die gezeigte Internalisierung des Proteins HBV-TLM-bCD erfolgte effizient und schnell und war unabhängig vom endosomalen Aufnahmeweg. Bei der nachgewiesenen Translokalisation blieb die enzymatische, suizidgentherapeutische Aktivität des zellpermeablen Suizidproteins (HBV-TLM-bCD), d.h. die katalytische Wirkung bei der Umsetzung der Prodroge 5-Fluorcytosin vollständig erhalten, so dass sich dieses Fusionsprotein für einen therapeutischen Einsatz in der Suizidgentherapie eignet. Zusätzlich zur antitumoralen Wirkung können durch einen gezielten, lokal begrenzten therapeutischen Einsatz der vorgestellten zellpermeablen bCD-HBV-TLM-Fusionsproteine starke Nebenwirkungen, wie sie bei einer konventionellen Chemotherapie zu beobachten sind, weitgehend vermieden werden. / This work investigates the application of protein based therapeutic suicide enzyme/prodrug approaches providing novel means for both safe and effective local therapeutic regimes in solid tumors. The concept of the used suicide gene therapy system is based mainly on the transfer of the cell permeable bacterial suicide enzyme cytosine deaminase which specifically convert the inactive, non-toxic prodrug 5-fluorocytosine into the toxic metabolite 5-fluorouracil finally executing the efficient destruction of tumor cells. Employing a novel cell permeable peptide, known as the translocation motif (TLM) of hepatitis B virus (HBV), E.coli cytosine deaminase (bCD) suicide fusion proteins were generated. HBV-TLM fusion proteins formed hexamers (as do parental wt bCD) and retained the specific enzymatic activity of cytosine conversion to uracil also being comparable to parental wtbCD protein. However, only bCD-HBV-TLM fusion proteins, but not HBV-TLM-bCD fusion proteins were found to be taken up to the cytoplasm of target hepatoma cells as demonstrated both by confocal laser scanning microscopy and cell fractionation. Uptake of bCD-HBV-TLM worked both efficiently and rapidly and was found to be independent from the endosomal pathway. Since bCD-HBV-TLM fusion proteins completely retained their suicide enzymatic activity in the course of translocation across the plasma membrane their usage as profound inducers of chemo-sensitivity to 5-fluorocytosine strongly is suggested. Future therapeutic local application of cell permeable bCD-HBV-TLM fusion proteins together with a systemic 5-fluorocytosine prodrug application could result in profound antitumor activities without apparent side effects.
|
7 |
Hepatozelluläres KarzinomLang, Hauke January 2009 (has links)
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
|
Page generated in 0.1052 seconds